(Editor’s note: This story has been updated to include NAGE stock movement)
Niagen Bioscience (NASDAQ:NAGE), the maker of anti-ageing supplements used by longevity entrepreneur Bryan Johnson, reaffirmed its 2026 sales growth outlook on Wednesday, after reporting first-quarter results that showed steady revenue gains and expanding investments into new product categories.
Shares of the company dropped over 7% in after-hours trading.
2026 Outlook Reaffirmed As Marketing Spend Rises
The company said it still expects full-year net sales to grow 10%-15%, excluding revenue from its divested Analytical Reference Standards and Services unit, driven by e-commerce momentum and new strategic partnerships.
Niagen also updated its general and administrative expense outlook for the year to an increase of $3 million-$4 million, compared to prior guidance of $4 million-$5 million, while flagging higher sales and marketing spending to support customer acquisition and new vertical launches.
data-variant=”card”
data-news-mode=”manual”
>
